DocMorris Stock Soars After Deutsche Bank Upgrade, Price Target Doubled

DocMorris (DOCM) shares surged on Monday after Deutsche Bank upgraded the online pharmacy to Buy from Hold, more than doubling its price target to CHF 11.50 from CHF 5.50. The stock climbed as much as 12.8% to trade at CHF 9.68, hitting a new 52-week high of CHF 9.94 intraday.

Analyst's Rationale

In a note to clients, Deutsche Bank analyst Jan Koch outlined four key drivers for the upgraded stance, arguing that the market is underappreciating the company's potential. The bank's conviction is based on:

• Probable upside to DocMorris's 2026 revenue guidance.
• Significantly reduced requirements for external funding.
• A more favorable regulatory environment in its key German market.
• The unrecognized value of its TeleClinic telemedicine asset.

The analyst stated that the company's investment narrative is now decisively shifting toward earnings growth and cash flow improvement, providing a strong foundation for the bullish re-rating.

Near-Term Catalysts and Company Strategy

Ad

The timing of the upgrade amplified its market impact, coming just two trading sessions before DocMorris is scheduled to release its first-half 2026 trading update. This has raised investor expectations for a positive report.

Confidence in the company's trajectory is further supported by its own recent announcements. In late June, DocMorris flagged accelerating revenue momentum in the second quarter. It also unveiled an "AI-First" strategy aimed at achieving at least CHF 15 million in annual cost savings through automation and a workforce reduction of approximately 100 full-time positions, reinforcing its path toward free cash flow break-even.

Market Impact and Competitive Landscape

Monday's double-digit gain extended the stock's year-to-date advance to approximately 46%. The strong positive sentiment from the analyst upgrade appeared to override recent concerns about new competition.

Last week, German drugstore giant Rossmann announced its entry into the mail-order pharmacy market, creating a new headwind for DocMorris. While this news had previously weighed on the stock, the market on Monday focused on the company's improving financial outlook as detailed by Deutsche Bank.